✦ LIBER ✦

Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis

✍ Scribed by D. L. VEENSTRA; D. E. SPACKMAN; A. BISCEGLIE; K. V. KOWDLEY; R. G. GISH

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of lamivudin

✍ M. BUTI; M. A. CASADO; J. L. CALLEJA; J. SALMERÓN; J. AGUILAR; M. RUEDA; R. ESTE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

PIH31 Anti-Viral Treatment of Chronic He

✍ P. Mernagh; S. Norris; M. Del Cuore 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PIN67 Cost-Effectiveness Analysis of Peg

✍ M. Jakubczyk; J. Pawèska; M. Niewada; H. Berak; M. Szkultecka-dèbek; M. Russel-s 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PIN5 THE COST EFFECTIVENESS ANALYSIS OF

✍ E Kowalik; M Niewada; M Jakubczyk; A Horban; H Berak; M Szkultecka-Debek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

559 COST-EFFECTIVENESS SIMULATION ANALYS

✍ B. Deniz; F. Everhard 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 54 KB

PIN31 COST-EFFECTIVENESS ANALYSIS OF TEL

✍ Chen, W; Hou, J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB